Abstract
Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor - BAYx1005 given at a dose of 1.88 mg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR - DKO mouse model BAYx1005 inhibited atherogenesis, measured both by "en face" method (23.84 +/- 2.7% vs. 15.16 +/- 1.4%) and "cross-section" method (497236 +/- 31516 microm(2) vs. 278107 +/- 21824 microm(2)). This is the first report that shows the effect of BAYx1005 on atherogenesis in gene-targeted mice.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Aorta / drug effects
-
Aorta / metabolism
-
Aorta / pathology
-
Apolipoproteins E / genetics*
-
Apolipoproteins E / metabolism
-
Atherosclerosis / drug therapy*
-
Atherosclerosis / genetics
-
Atherosclerosis / metabolism
-
Azo Compounds / chemistry
-
Female
-
Lipoxygenase Inhibitors / chemistry
-
Lipoxygenase Inhibitors / pharmacology
-
Lipoxygenase Inhibitors / therapeutic use
-
Mice
-
Mice, Inbred C57BL
-
Mice, Knockout
-
Molecular Structure
-
Quinolines / chemistry
-
Quinolines / pharmacology*
-
Quinolines / therapeutic use
-
Receptors, LDL / genetics*
-
Receptors, LDL / metabolism
-
Staining and Labeling / methods
Substances
-
Apolipoproteins E
-
Azo Compounds
-
Lipoxygenase Inhibitors
-
Quinolines
-
Receptors, LDL
-
2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid
-
oil red O